Losartan Market Report 2026

The losartan market size has grown steadily in recent years. It will grow from $1.49 billion in 2025 to $1.55 billion in 2026 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to increasing global hypertension burden, widespread clinical adoption of arbs, rising incidence of diabetes-related kidney disease, improved awareness of cardiovascular risk management, early shift from ace inhibitors to arbs.

The losartan market size is expected to see steady growth in the next few years. It will grow to $1.83 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to aging population growth, rising demand for kidney-protective antihypertensive drugs, expanding access to affordable generics, increasing focus on stroke prevention, higher healthcare spending on chronic disease treatment. Major trends in the forecast period include rising prevalence of hypertension and cardiovascular disorders, growing preference for arbs over ace inhibitors, expansion of generic losartan prescriptions, increasing use in diabetic nephropathy management, rising long-term blood pressure control therapy adoption.

The increasing prevalence of hypertension is expected to drive the growth of the losartan market in the coming years. Hypertension is a condition characterized by consistently high blood pressure, which can increase the risk of heart disease, stroke, and other serious health complications. The rising occurrence of hypertension is associated with diets high in salt and processed foods, leading to fluid retention and added strain on the heart. Losartan helps manage hypertension by blocking angiotensin II, a hormone that constricts blood vessels. This action relaxes and widens the vessels, reducing blood pressure and lessening the heart's workload. For example, in January 2025, according to the Centers for Disease Control and Prevention, a US-based organization, high blood pressure was a primary or contributing factor in 664,470 deaths in the United States in 2023. Consequently, the rising prevalence of hypertension is fueling the growth of the losartan market.

Major companies operating in the losartan market are concentrating on developing innovative products and obtaining approvals, such as losartan potassium oral suspension, to improve patient adherence and broaden therapeutic uses. Losartan potassium oral suspension is a liquid form of the medication losartan potassium, designed for individuals who have difficulty swallowing tablets. For example, in March 2025, Scienture Holdings Inc., a US-based biopharmaceutical company, obtained Food and Drug Administration (FDA) approval for Arbli. This is a ready-to-use liquid formulation for hypertension, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and treating diabetic nephropathy in type 2 diabetes patients. It provides accurate dosing without the need for compounding and is offered in a 165 mL peppermint-flavored suspension (10 mg/mL) with an 18-month shelf life at room temperature.

In April 2025, Scienture Holdings, Inc., a US-based losartan manufacturer, collaborated with Saptalis Pharmaceuticals to produce Arbli, a losartan potassium oral suspension (10 mg/mL). The partnership includes warehousing and distribution arrangements with strategic partners to ensure market availability of the first FDA-approved ready-to-use oral liquid losartan, addressing unmet needs in hypertension management. Saptalis Pharmaceuticals is a US-based pharmaceutical company.

Major companies operating in the losartan market are Viatris Inc., Teva Pharmaceutical Industries Ltd, Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Cadila Pharmaceuticals Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Vasudha Pharma Chem Ltd., Unichem Laboratories Ltd., Global Pharma Tek, Manus Aktteva Biopharma LLP, Emcure Pharmaceuticals Ltd., Wellona Pharma, JPM Pharma & Chemicals Pvt. Ltd.

North America was the largest region in the losartan market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the losartan market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the losartan market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the losartan market by increasing costs related to imported active pharmaceutical ingredients and bulk drug intermediates. These effects are more pronounced for branded and higher-dosage formulations, particularly in regions such as asia-pacific and europe that rely on global pharmaceutical supply chains. Online and offline distribution channels face pricing pressure due to increased procurement costs. However, tariffs have encouraged domestic manufacturing, strengthened generic drug production, and improved regional supply chain resilience over the long term.

The losartan market research report is one of a series of new reports that provides losartan market statistics, including losartan industry global market size, regional shares, competitors with a losartan market share, detailed losartan market segments, market trends and opportunities, and any further data you may need to thrive in the losartan industry. This losartan market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Losartan is an angiotensin II receptor blocker (ARB) frequently prescribed to manage high blood pressure and lower the risk of stroke in patients with hypertension. It functions by relaxing blood vessels, making it easier for the heart to pump blood. Losartan helps reduce blood pressure, supports heart function, and protects kidney health, particularly in patients with diabetes.

The primary forms of losartan dosage include tablets, powder, and suspension. Losartan tablets are convenient, once-daily oral medications used to treat hypertension and diabetic nephropathy. It is obtained from various sources, such as contract manufacturing organizations and in-house production, and is distributed through multiple channels, including online and offline. It is used for different conditions, such as hypertension, stroke, diabetic nephropathy, and others, and is taken by various end-users, including adults and children.

The losartan market consists of sales of losartan potassium tablets, losartan-hydrochlorothiazide combination tablets, and generic formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.